FDA, Weight loss

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA Approves Weight Loss Medication Zepbound to Treat Sleep Apnea
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” In addition to the GLP-1 prescription, the FDA suggests that users reduce their calorie intake and increase their exercise.
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
FDA warns companies over unapproved weight loss drug sales
The Food and Drug Administration (FDA) announced in a statement Tuesday that it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides,
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Daily3d
Tirzepatide taken for weight loss may lead to Colonic Ischemia: Case report
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
BioSpace3d
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...